Eledon Pharmaceuticals and NewcelX have entered into a collaboration to advance NewcelX’s stem‑cell‑derived islet therapy, NCEL‑101, for type 1 diabetes. The partnership positions Eledon’s CD40‑L antibody platform, tegoprubart, as a key immune‑protective component for the cell therapy, while NewcelX supplies the islet cells and manufacturing expertise.
The collaboration includes a $3.4 million financing for NewcelX, consisting of $1.35 million in cash and up to $2 million in potential proceeds from warrant exercise. NewcelX also retains access to a $25 million equity line of credit, providing additional liquidity for the joint program. NewcelX reported a net loss of $8.3 million for 2025, underscoring the importance of the new capital infusion.
Eledon’s tegoprubart has Orphan Drug Designation for islet cell transplantation and has been used in over 100 transplant patients, giving the company a strong clinical foundation for its role in the partnership. NewcelX’s NCEL‑101 aims to deliver a functional cure for type 1 diabetes by transplanting stem‑cell‑derived islet cells protected by Eledon’s antibody platform.
The collaboration expands Eledon’s pipeline beyond kidney transplantation into a high‑growth therapeutic area. Management has highlighted the strategic fit: NewcelX’s executive chairman and CEO, Ronen Twito, described the partnership as the flagship program for the company, while Eledon’s CEO, David‑Alexandre C. Gros, noted that tegoprubart’s safety profile could address key issues in current transplant immunosuppression. The deal is expected to accelerate IND‑enabling milestones for NCEL‑101 and strengthen investor confidence in both companies.
The announcement was well received by investors, reflecting confidence in the scientific synergy and the potential for a functional cure in type 1 diabetes. The partnership positions both companies to capitalize on a market projected to grow from $3.01 billion in 2025 to $3.38 billion in 2026, with a 12.2% CAGR.
The collaboration is expected to accelerate the development of NCEL‑101, with Eledon’s immune‑protective platform potentially improving graft survival and reducing rejection risk. The partnership also diversifies Eledon’s revenue streams and enhances its competitive positioning in the emerging cell‑therapy market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.